hyperkalemia
- Business Wire
First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment
CARE-HK in heart failure (HF) is the first global registry of around 5,000 patients with chronic HF who have or…
Read More » - World
VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa® agreement
Bad Homburg, Germany & St. Gallen, Switzerland: Veltassa® is a well-tolerated1 and effective2 oral calcium potassium binder for the treatment of hyperkalemia supported…
Read More » - United States
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 percent in adults with and without diabetes who had heart failure with reduced ejection fraction
Ingelheim, Germany & Indianapolis, United States: Empagliflozin also significantly reduced the relative risk of first and recurrent hospitalization for heart…
Read More »